Abstract
Fifteen patients undergoing surgery for Stage IIb malignant melanoma were randomly allocated either to a group who received a vaccine of BCG mixed with irradiated autologous melanoma cells, or a control group who received no further treatment. All patients were monitored sequentially for immunological competence and tumour-directed immunity, using a wide range of techniques, and the results were compared retrospectively with their clinical course. Three months after surgery, there was a trend towards inhibition of PHA-induced lymphocyte transformation by autologous serum in patients who developed recurrent tumour within 12 months after treatment. Serum from patients who remained tumour-free for 12 months did not inhibit stimulation of autologous lymphocytes by PHA. Apart from this test, no other immunological parameters correlated either with clinical course or with the type of treatment received.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Amlot P. L., Unger A. Binding of phytohaemagglutinin to serum substances and inhibition of lymphocyte transformation in Hodgkin's disease. Clin Exp Immunol. 1976 Dec;26(3):520–527. [PMC free article] [PubMed] [Google Scholar]
- Currie G. A., McElwain T. J. Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study. Br J Cancer. 1975 Feb;31(2):143–156. doi: 10.1038/bjc.1975.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Embleton M. J., Wagner J. C., Wagner M. M., Jones J. S., Sheers G., Oldham P. D., Baldwin R. W. Assessment of cell-mediated immunity to malignant mesothelioma by microcytotoxicity tests. Int J Cancer. 1976 May 15;17(5):597–601. doi: 10.1002/ijc.2910170507. [DOI] [PubMed] [Google Scholar]
- Hellström I., Warner G. A., Hellström K. E., Sjögren H. O. Sequential studies on cell-mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma. Int J Cancer. 1973 Mar 15;11(2):280–292. doi: 10.1002/ijc.2910110206. [DOI] [PubMed] [Google Scholar]
- Heppner G. H., Stolbach L., Byrne M., Cummings F. J., McDonough E., Calabresi P. Cell-mediated and serum blocking reactivity to tumor antigens in patients with malignant melanoma. Int J Cancer. 1973 Mar 15;11(2):245–260. doi: 10.1002/ijc.2910110202. [DOI] [PubMed] [Google Scholar]
- Lieberman R., Wybran J., Epstein W. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma. Cancer. 1975 Mar;35(3):756–777. doi: 10.1002/1097-0142(197503)35:3<756::aid-cncr2820350331>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
- Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
- McCoy J. L., Jerome L. F., Dean J. H., Perlin E., Oldham R. K., Char D. H., Cohen M. H., Felix E. L., Herberman R. B. Inhibition of leukocyte migration by tumor-associated antigens in soluble extracts of human malignant melanoma. J Natl Cancer Inst. 1975 Jul;55(1):19–23. doi: 10.1093/jnci/55.1.19. [DOI] [PubMed] [Google Scholar]
- McIllmurray M. B., Embleton M. J., Reeves W. G., Langman M. J., Deane M. Controlled trial of active immunotherapy in management of stage IIB malignant melanoma. Br Med J. 1977 Feb 26;1(6060):540–542. doi: 10.1136/bmj.1.6060.540. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Spitler L. E., Levin A. S., Wybran J. Combined immunotherapy in malignant melanoma. Regression of metastatic lesions in two patients concordant in timing with systemic administration of transfer factor and Bacillus Calmette-Guérin. Cell Immunol. 1976 Jan;21(1):1–19. doi: 10.1016/0008-8749(76)90322-1. [DOI] [PubMed] [Google Scholar]